Companies and Strategies in the High-Strength Surgical Sealant Market

UPDATE: See See the 2012 report #S190, “Worldwide Market for Surgical Sealants, Glues, Wound Closure and Anti-Adhesion, 2012-2017”.

A number of market leaders have consolidated their positions within the surgical closure and securement markets through successful internal development programs and through technology partnerships with innovative vendors of next-generation technologies. For example, Covidien and Ethicon (Johnson & Johnson) are major suppliers of cyanoacrylate products in the United States; with dominant sales resources to sell these products, these companies lead the market, although they face competition from the Canadian company Glustitch, the U.K.-based Medlogic and others. Synovis (formally Biovascular Inc.) has targeted cardiovascular and other procedures, and has a range of closure products; it has partnered with GEM to develop and exploit GEM’s internal high-strength glue product (Glubran) in the United States. See below for summary of strategies of these companies.

Selected High-Strength Adhesive Companies and Their Strategies

Wound Type

Worldwide Prevalence (Thousands)

Healing Time (Days)

CAGR (2012-2020)

Surgical wounds

114,271

14

3.6%

Traumatic wounds

1,627

28

1.7%

Lacerations

20,645

14

1.2%

Burn wounds

10,221

21

1.2%

Chronic wounds*

40,400

--

7.6%

Carcinomas

618

14

3.0%

Melanoma

103

14

3.2%

Complicated skin cancer

103

28

3.1%

Source: MedMarket Diligence, LLC; Updated Report #S190

Companies in the sealant market are also highly competitive, and acquisitions and mergers have also played a significant role in shaping this market, the individual companies, their products and underlying strategic focus. For example, Baxter progressed fibrin sealant technology (purchased through its acquisition of Immuno Inc.) to market in the United States and, also as a result of purchase of Immuno in 1998, was forced to give up a monopoly position by forming a partnership with Haemacure to allow them to also market fibrin products in the United States. Baxter’s acquisition of Fusion Inc.’s technology created a portfolio of sealant products. CryoLife Inc. has demonstrated the potential to compete within the rapidly evolving sealants market in the United States by developing superior products.


See the 2012 MMD report, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Market, 2010-2017.” Report #S190.